Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...